Company: HSDTW
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001104659-25-035130
Chunk: 14

Company: Solana Co
Filing Date: 2025-04-15
Form: DRS
Chunk 14
---
 under the caption “Risk Factors” beginning on page 9of this prospectus and the other information included elsewhere and incorporated by reference in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.

#### Exchange Listing
Our common stock is listed on Nasdaq under the ticker symbol “HSDT.” There is no established trading market for the common warrants or the pre-funded warrants, and we do not expect a trading market to develop. We do not intend to list the common warrants or the pre-funded warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the common warrants and the pre-funded warrants will be extremely limited.

The number of shares of our common stock to be outstanding after this offering as shown above is based on 6,126,778 shares outstanding as of March 31, 2025, and excludes:

•

2,729,689 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $7.30 per share;

•

7,701,548 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $1.77 per share;

•

123,989 shares of our common stock to be reserved for potential future issuance pursuant to the Helius Medical Technologies, Inc. 2021 Inducement Plan (the “2021 Plan”) and the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the “2022 Plan”); and

•

2,678,000 shares held in abeyance.

<div align='center'>7</div>

TABLE OF CONTENTS

### CONFIDENTIAL TREATMENT REQUESTED

#### PURSUANT TO 17 C.F.R. SECTION 200.83
Unless otherwise indicated, this prospectus reflects and assumes the following:

•

no exercise of outstanding options or warrants after March 31, 2025 (including the common warrants, pre-funded warrants and representative warrants offered hereby); and

•

no exercise by the underwriters of their option to purchase additional securities of common stock in this offering.

<div align='center'>8</div>

TABLE OF CONTENTS

### CONFIDENTIAL TREATMENT REQUESTED

#### PURSUANT TO 17 C.F.R. SECTION 200.83

### RISK FACTORS
An investment in our securities has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties described below and in the “Risk Factors” section of